TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition

José Luis Granados-Soler1,5, Johannes Junginger2, Marion Hewicker-Trautwein2, Kirsten Bornemann-Kolatzki3, Julia Beck3, Bertram Brenig4, Daniela Betz1, Jan Torben Schille1,5, Hugo Murua Escobar1,5 & Ingo Nolte1

Feline mammary carcinomas (FMCs) with anaplastic and malignant spindle cells histologically resemble the human metaplastic breast carcinoma (hMBC), spindle-cell subtype. hMBCs display epithelial-to-mesenchymal transition (EMT) characteristics. Herein we report the establishment and characterization of a cell line (TiHoCMglAdcar0906; TiHo-0906) exhibiting EMT-like properties derived from an FMC with anaplastic and malignant spindle cells. Copy-number variations (CNVs) by next-generation sequencing and immunohistochemical characteristics of the cell line and the tumour were compared. The absolute qPCR expression of EMT-related markers HMGA2 and CD44 was determined. The growth, migration, and sensitivity to doxorubicin were assessed. TiHo-0906 CNVs affect several genomic regions harbouring known EMT-, breast cancer-, and hMBCs-associated genes as AKT1, GATA3, CCND2, CDK4, ZEB1, KRAS, HMGA2, ESRP1, MTDH, YWHAZ, and MYC. Most of them were located in amplified regions of feline chromosomes (FCAs) B4 and F2. TiHo-0906 cells displayed an epithelial/mesenchymal phenotype, and high HMGA2 and CD44 expression. Growth and migration remained comparable during subculturating. Low-passaged cells were two-fold more resistant to doxorubicin than high-passaged cells (IC50: 99.97 nM, and 41.22 nM, respectively). The TiHo-0906 cell line was derived from a poorly differentiated cellular subpopulation of the tumour consistently displaying EMT traits. The cell line presents excellent opportunities for studying EMT on FMCs.

Feline mammary carcinomas (FMCs) with anaplastic and malignant spindle cells histologically resemble the human metaplastic breast carcinoma (hMBC), spindle-cell subtype. hMBCs display epithelial-to-mesenchymal transition (EMT) characteristics. Herein we report the establishment and characterization of a cell line (TiHoCMglAdcar0906; TiHo-0906) exhibiting EMT-like properties derived from an FMC with anaplastic and malignant spindle cells. Copy-number variations (CNVs) by next-generation sequencing and immunohistochemical characteristics of the cell line and the tumour were compared. The absolute qPCR expression of EMT-related markers HMGA2 and CD44 was determined. The growth, migration, and sensitivity to doxorubicin were assessed. TiHo-0906 CNVs affect several genomic regions harbouring known EMT-, breast cancer-, and hMBCs-associated genes as AKT1, GATA3, CCND2, CDK4, ZEB1, KRAS, HMGA2, ESRP1, MTDH, YWHAZ, and MYC. Most of them were located in amplified regions of feline chromosomes (FCAs) B4 and F2. TiHo-0906 cells displayed an epithelial/mesenchymal phenotype, and high HMGA2 and CD44 expression. Growth and migration remained comparable during subculturating. Low-passaged cells were two-fold more resistant to doxorubicin than high-passaged cells (IC50: 99.97 nM, and 41.22 nM, respectively). The TiHo-0906 cell line was derived from a poorly differentiated cellular subpopulation of the tumour consistently displaying EMT traits. The cell line presents excellent opportunities for studying EMT on FMCs.

Feline mammary carcinomas are the third most common neoplasms in female cats1. The feline mammary tissue encompasses three tissue lineages, the luminal epithelial, the myoepithelial, and the mesenchymal2. Around 90% of feline mammary neoplasms are luminal epithelial tumours usually referred to as FMCs2,3. FMCs are invasive tumours characterized by early metastasis4,5. FMCs with anaplastic and malignant spindle cells are uncommon, and their distinctive morphologic features are not described in any of the subtypes included in the latest classification published by the World Health Organization (WHO)2. The genetic determinants of the neoplastic spindle-cell component in FMCs are still unclear, and little is known about the biological behavior of these tumours and prognosis of the affected animals.

1Small Animal Clinic, University of Veterinary Medicine Hannover Foundation, Hannover, Germany. 2Department of Pathology, University of Veterinary Medicine Hannover Foundation, Hannover, Germany. 3Chronix Biomedical, Göttingen, Germany. 4Institute of Veterinary Medicine, University of Göttingen, Göttingen, Germany. 5Department of Internal Medicine, Medical Clinic III, Clinic for Haematology, Oncology and Palliative Care, University Medical Center Rostock, Rostock, Germany. Hugo Murua Escobar and Ingo Nolte contributed equally. Correspondence and requests for materials should be addressed to I.N. (email: Ingo.Nolte@tiho-hannover.de)
FMCs with malignant anaplastic and spindle cells share some histological characteristics with the highly malignant hMBCs, spindle-cell subtype. Histologically, hMBCs display epithelial differentiation towards mesenchymal elements (chondroid, osseous, rhabdoid, and spindle)\(^5\). Around 80% of hMBCs are spindle-cell tumours frequently enriched in EMT features\(^6–8\). EMT is an embryonic process reactivated in adult tissues during cicatization, fibrosis, and cancer\(^9\). During EMT, epithelial cells lose expression of cell-cell junction proteins and gain the expression of mesenchymal proteins\(^10\). Afterwards, the EMT-derived cells secrete proteolytic enzymes (metallo-proteinases), which degrade the extracellular matrix and cell-cell junctions, facilitating detachment, mobility, and metastasis\(^11\). EMT results in enhanced migratory capacity\(^7,10\), cancer stem cells (CSCs) properties\(^9,12–15\), and drug resistance\(^8,16,17\). Usually, neoplastic cells do not experience a full EMT, instead, they assume different phenotypes along the epithelial-mesenchymal axis\(^17–20\).

The EMT is regulated by several cytokines and growth factors\(^9,15,21\). Consequently, it has been induced in cell culture by different methods\(^13,14,22,23\). The High-mobility group AT-hook 2 protein (HMGA2) activates a range of EMT transcription factors implicated in the repression of epithelial genes, and mesenchymal genes up-regulation\(^24,25\). Therefore, EMT-derived cells are usually characterized by a higher HMGA2 expression\(^26,27\), loss or reduced expression of E-cadherin (E-cad), up-regulation of vimentin (Vim)\(^7\), and co-expression of epithelial markers (cytokeratins [CKs]) and mesenchymal markers (calponin [CALP], smooth muscle actin [SMA], and Vim)\(^27\). Other markers like CD44 participate in the downregulation of E-cad\(^12,28\). Consequently, EMT-derived cells are characterized by a higher CD44 expression\(^28,29\). The overexpression of this cell surface protein leads to enhanced cell migration, cancer invasion and metastasis\(^29\). Additionally, a higher CD44 expression in combination with other surface markers is used for CSCs identification\(^29,30\).

CNVs (copy-number gains [CNGs], and copy-number losses [CNLs]) are structural aberrations usually affecting extensive regions of the genome\(^31\). CNVs affect the gene expression patterns by altering the gene dosage in human breast cancer\(^32–34\), hMBCs\(^3,32\), and breast cancer cell lines\(^35\). Additionally, specific CNGs are concordant with EMT-related genes up-regulation in multiple human cancer types\(^36\). Cancer cell lines are characterized by genomic instability and structural dynamism\(^37–39\), which makes CNVs a suitable tool to understand cancer cell adaptation to the in vitro environment during cell culture establishment and clonal selection during subculturing. To the extent of our knowledge, this is the first study characterizing CNVs in an FMC cell line. This study reports on the establishment and comprehensive characterization of a cell line TiHo-0906 derived from a poorly differentiated FMC with anaplastic and spindle cells. The original tumour and the derived cell line were enriched with EMT-associated traits.

**Results**  
**Histopathological description of the tumour.** Histologically, the tumour was mainly composed of malignant spindle cells, malignant tubular epithelial cells, and small areas with anaplastic polygonal cells. The mammary gland was infiltrated by a multinodular invasive growing neoplasm. Some areas were characterized by cuboidal to columnar epithelial cells that formed irregular tubular structures by palisading along a basement membrane (Fig. 1a). These cells showed distinct cytoplasmic borders, moderate amounts of eosinophilic cytoplasm and central round basophilic nuclei with finely stippled chromatin and distinct nucleoli. In addition, there were multifocal areas in which neoplastic cells were arranged in solid nests of variable size with anaplastic morphology lacking tubular differentiation (Fig. 1b). Cells in these areas were featured by a polygonal shape with mostly well-defined cell borders and low to moderate amounts of eosinophilic cytoplasm. Their large prominent centrally arranged basophilic round to oval nuclei revealed a finely to coarsely stippled chromatin pattern and distinct prominent nucleoli. In contrast, some areas were dominated by closely packed spindle cells with low amounts of cytoplasm and oval to elongated basophilic nuclei containing finely stippled chromatin and distinct nucleoli (Fig. 1c). Predominating within the anaplastic foci, the cells were featured by moderate anisokaryosis and anisocytosis and occasionally contained multiple nuclei. Mitotic figures averaged three per high power field. Clusters of tumour cells were also present within some lymphatic vessels. Multifocally, there were single cells or coalescing necrosis characterized by hyper eosinophilia and nuclear pyknosis, rhexis and lysis. Neoplastic cells were supported by low to moderate amounts of collagen-rich fibrovascular stroma that showed multifocal infiltration by moderate numbers of lymphocytes and plasma cells as well as variable numbers of neutrophils.
Cytomorphologic features of the cell line. After cell culture establishment, TiHo-0906 cells proliferated in a monolayer. Subconfluent cells were spindle-shaped with a bipolar to multipolar morphology (Fig. 2a). At confluence, cells revealed a more epithelioid morphology with polygonal to bipolar shape (Fig. 2b). Cellular morphology and proliferation rate remained stable during prolonged subculturing (over 100 passages). Microscopic examination of TiHo-0906 cells in H&E stained paraffin sections from pellets revealed round to polygonal cells and a moderate to partly abundant cytoplasm. They had large, prominent, round to oval nuclei that showed moderate to severe atypia and contained coarsely stippled to vesiculated chromatin and distinct nucleoli. TiHo-0906 cells were further characterized by marked anisokaryosis and anisocytosis, atypical mitotic figures and several large multinucleated syncytia (Fig. 2c).

Tumour immunophenotyping. Tumours displaying EMT features usually express epithelial and mesenchymal markers concurrently. In general, a co-expression of epithelial markers and Vim was observed in tubular and solid anaplastic areas of the tumour. In contrast, spindle cells were negative to all epithelial markers and positive to all mesenchymal markers used. Additionally, all parts of the tumour were negative to the specific myoepithelial markers cytokeratin 5/6 (CK5/6) and p63 (Table 1).

Figure 2. Cellular morphology. (a) TiHo-0906 P76 cell culture at subconfluence, inverted microscopy. Bipolar to multipolar shaped cells (arrows). (b) TiHo-0906 P76 cell culture at confluence, inverted microscopy. Monolayer of epithelial-like cells characterized by polygonal (circles) to bipolar morphology (arrows). (c) TiHo-0906 P79 pellet; paraffin sections, H&E. Round to polygonal shaped cells characterised by marked anisokaryosis and anisocytosis, atypical mitotic figure (arrow) and large multinucleated syncytia (arrowheads).

| Marker   | Tubuli-forming cells | Polygonal cells | Spindle cells |
|----------|----------------------|-----------------|--------------|
| E-cad    | +                    | −               | −            |
| CK8/18   | +                    | +               | −            |
| pan-CK   | +                    | +               | −            |
| CK14     | +                    | +               | −            |
| CK5/6    | −                    | −               | −            |
| p63      | −                    | −               | −            |
| SMA      | −                    | +               | +            |
| CALP     | −                    | +               | +            |
| Vim      | +                    | +               | +            |
| CD44     | +                    | +               | +            |

Table 1. Comparative expression profile of the original tumour. + Positive, − Negative.
slightly positive in tubular and polygonal cells; spindle cells were negative. Additionally, a high Ki-67 proliferation index was observed in all areas of the tumour. Results of the immunohistochemical characteristics of the tumour are detailed in Table 2.

**Cell line phenotyping.** TiHo-0906 cells at low and high passage reacted similarly to the markers employed; all pellets evaluated coexpressed epithelial and mesenchymal markers (Table 3).

The immunohistochemical characteristics of the cell line resembled those of the polygonal epithelial cells present in the anaplastic areas of the tumour with exception of E-cad that was positive in most TiHo-0906 cells at low (Fig. 4a) and high passages (Fig. 4b). TiHo-0906 cells at low (Fig. 4c) and high passages (Fig. 4d) were positive for pan-CK, and Vim (Fig. 4e). Interestingly, some of the pellets evaluated in both low- and high-passaged cells were positive for the myoepithelial marker p63 (Fig. 4g, low-passaged cells), while the tumour was negative. An intense membrane staining for CD44 was observed on almost 100% of the cells in all pellets evaluated (Fig. 4h, low and high passages respectively).
TiHo-0906 cells were slightly positive to the hormonal receptors (ER, PR), and HER-2. COX-2 labelling was negative in all of the pellets evaluated. p53 was moderately expressed in all of the pellets evaluated. CLDN-2 was weakly expressed in all pellets (score 1 to 3) \(^{42}\). The mean Ki-67 proliferation index of TiHo-0906 cells in pellets was 39.3% and 42.2% in early and high passages, respectively.

**Copy number variation analysis.** TiHo-0906 cells at low (P7) and high (P79) passages showed a high level of genomic instability when compared to the original tumour. The frequency of CNVs in TiHo-0906 cells increased during *in vitro* culturing. FCAs B2, B3, B4, and F2 in TiHo-0906 cells displayed most of the genomic regions with CNGs (Fig. 5).

CNGs in chromosomes B2, B4 and F2 remained similar during subculturing. Interestingly, chromosomes B4 and F2 harbour some of the previously reported EMT-implicated genes associated with more frequent CNGs in different types of human cancer \(^ {36} \) (Table 4).

In general, the amount of CNLs also increased during cultivation. High-passaged TiHo-0906 cells showed losses on proximal chromosome A1, distal chromosome A2 and a focal deletion on chromosome E1 that were not observed in low-passaged cells. However, low-passaged TiHo-0906 cells showed a focal deletion of proximal chromosome E1 that was not observed in high-passaged cells. Additionally, the size of CNLs observed in chromosome E3 decreased during sub-cultivation. Some of the most important breast cancer-related genes in humans are located in the analysed corresponding feline regions \(^ {7,32,33} \) showing amplifications as well as deletions (details in Table 5).

**Real-time PCR expression analyses of HMGA2 and CD44.** The levels of HMGA2 and CD44 in TiHo-0906 cells were examined by absolute RT-PCR and compared to the corresponding reference tissues (feline testis, and healthy mammary feline tissue, respectively). The level of HMGA2 expression in low and high passages was higher than those of the reference tissue (\( p = 0.001 \), and \( p < 0.0001 \), respectively). Similarly, the CD44 absolute expression in TiHo-0906 cells at low and high passages was significantly higher in comparison to the reference tissue (\( p = 0.01 \), and \( p = 0.0015 \), respectively). No significant differences in HMGA2 and CD44 expression were observed between low and high passages (Fig. 6).

**Growth behaviour and migration activity.** No statistical differences in BrdU incorporation and growth curves were found between low and high passages of the TiHo-0906 cell line (Fig. 7a,b). The doubling time for the cell line was 28.9 h at low passage and 27.4 h at high passage. Fourteen hours after the scratching, migrating cells completely covered the wound (400 \( \mu m \)) in early and high passages of the TiHo-0906 cell line (Fig. 7c–j). No significant differences regarding the time to wound closure were observed between low and high passages.

| Marker | TiHo-0906 early passage | TiHo-0906 high passage |
|--------|------------------------|------------------------|
|        | pellet 1 | pellet 2 | pellet 3 | pellet 1 | pellet 2 | pellet 3 |
| E-cad  | +        | +        | +        | +        | +        | +        |
| CK8/18 | +        | +        | +        | +        | +        | +        |
| pan-CK | +        | +        | +        | +        | +        | +        |
| CK14   | +        | +        | +        | +        | +        | +        |
| CK5/6  | −        | −        | −        | −        | −        | −        |
| p63    | −        | −        | +        | +        | −        | −        |
| SMA    | +        | +        | +        | +        | +        | +        |
| CALP   | +        | +        | +        | +        | +        | +        |
| Vim    | +        | +        | +        | +        | +        | +        |
| CD44   | +        | +        | +        | +        | +        | +        |

**Table 3.** Comparative expression profile of the cell line. + Positive, −Negative.

| Marker Tubuli-forming cells | Polygonal cells | Spindle cells |
|-----------------------------|-----------------|---------------|
| ER                          | 17.5%           | 0             |
| PR                          | 27.6%           | 0             |
| HER-2**                    | 0               | 1+            |
| COX-2*                     | 0               | 0             |
| p53                        | 6.3%            | 3.3%          |
| CLDN-2***                  | 8               | 6             |
| K67                         | 47.3%           | 24.5%         |

**Table 2.** Immunohistochemical characteristics of the tumour. *COX-2 scoring system\(^ {93} \), **HercepTest\(^ {94,95} \), ***CLDN2 scoring system\(^ {42} \).
Metabolic activity of TiHo-0906 cells after doxorubicin treatment. According to the MTS assay results, the metabolic activity of doxorubicin-treated TiHo-0906 cells at low and high passage starts to significantly decrease at 100 nM of doxorubicin ($p = 0.01$, and $p = 0.03$, respectively), for details see Fig. 8a. After incubation with different concentrations of doxorubicin, the metabolic activity of TiHo-0906 cells at low and high passages was not statistically different. However, the IC50 of cells at low passage was approximately 2-fold higher than the IC50 of cells at high passage (Fig. 8b,c).

Effects of doxorubicin on apoptosis and cytotoxicity. After exposure to different concentrations of doxorubicin during 72 h. The amount of intact cells at low and high passage decreased from 91.1% (SD, 0.4%), and 86.5% (SD, 4.3%) in non-treated cells to 55.8% (SD, 0.4%), and 58.1% (SD, 2.1%) at the highest concentration of doxorubicin (2000 nM). In contrast, the amount of cell debris was consistently low in non-treated cells and increased proportionally to the concentration of doxorubicin, ranging from 8.2% (SD, 0.5%), and 13.5% (SD, 4.3%) in untreated cells at low and high passage to 43.3% (SD, 3.7%), and 41.9% (SD, 2.6%) at 2000 nM of doxorubicin, respectively. Response to doxorubicin—in terms of amount of intact cells and cellular debris—was not significantly different between low and high passages at any of the doxorubicin concentrations tested (Fig. 9a).

Intact cells were gated for viability on three different subpopulations as follows: viable, apoptotic, and dead cells. A significant dose-dependent reduction of viable cells at low and high passages starts after 72 h incubation with 50 nM of doxorubicin ($p < 0.0001$, and $p = 0.0003$, respectively). Viable cells at low and high passage decreased from 96.9% (SD, 0.4%), and 97.2% (SD, 0.2%) in non-treated cells to 54.6% (SD, 10.6%), and 30.9% (SD, 0.7%) at 2000 nM doxorubicin. The number of living cells was significantly higher in low-passaged cells at 50 nM, 100 nM, 200 nM, 500 nM and 2000 nM doxorubicin, more details are shown in Fig. 9b.
Doxorubicin induces dose-dependent apoptosis in TiHo-0906 cells at low and high passages, ranging from 5.2% (SD, 1.4%), and 4.6% (SD, 0.7%) at 1 nM doxorubicin to 45.1% (SD, 10.6%), and 65.9% (SD, 1.6%) at 2000 nM doxorubicin. The amount of apoptotic cells was significantly higher in high-passaged cells at all doxorubicin concentrations up to 50 nM (Fig. 9c). Surprisingly, incubation with doxorubicin reduced the amount

![Figure 5. Comparative Circos plots of the original tumour and TiHo-0906 cells at low and high passages. Outer multicolor ring: chromosome location. Inner rings from the outside-in: original tumour, TiHo-0906 P7, and TiHo-0906 P76. Green lines indicate CNGs, and red lines indicate CNLs.](image)

| Gene          | Feline chromosome | Location (bp) | TiHo-0906 P7 | TiHo-0906 P76 |
|---------------|-------------------|---------------|--------------|--------------|
| EGFR          | A2                | 69,024,076–69,243,754 |             |              |
| TWIST1        | A2                | 113,452,909–113,454,730 |             |              |
| AKTI          | B3                | 148,724,327–148,745,203 | ↑           | ↑            |
| VIM           | B4                | 16,166,246–16,173,638 | ↑           | ↑            |
| ZEB1          | B4                | 28,693,675–28,892,926 | ↑           | ↑            |
| KRAS          | B4                | 60,631,473–60,670,232 | ↑           | ↑            |
| ESRP1         | F2                | 43,419,796–43,484,114 | ↑           | ↑            |
| MTDH          | F2                | 46,121,204–46,179,417 | ↑           | ↑            |
| YWHAZ         | F2                | 49,027,370–49,061,094 | ↑           | ↑            |
| MYC           | F2                | 70,514,069–70,519,083 | ↑           | ↑            |

Table 4. EMT-associated genes frequently affected by CNGs in multiple types of human cancer and their copy number status in TiHo-0906 cells. *Breast cancer-associated CNGs;**hMBCs-associated CNGs;***Breast cancer cell lines-associated CNGs.
of viable cells while increasing that of apoptotic cells but was not able to significantly increase the amount of dead cells. Nonetheless, part of the cell debris excluded from viability gating could represent fragments of dead cells. Incubation with 50 nM doxorubicin induced the highest amount of dead cells observed (5.9%; SD, 1.6%). Comparing low and high passages, the amount of dead cells was only higher in cells at high passage incubated with 2000 nM doxorubicin (Fig. 9d).

### Discussion

Epithelial to mesenchymal transition can be observed in vitro and has been immunohistochemically portrayed in mammary cancer in dogs and humans. The importance of EMT on FMCs has not been evaluated, and to the extent of our knowledge, EMT-associated genomic aberrations have not been documented in an FMC cell line. TiHo-0906 cells displayed a combined epithelial/mesenchymal phenotype and a high expression of EMT-related markers HMGA2 (qPCR) and CD44 (qPCR and immunohistochemistry). Moreover, the cell line
was characterized by stable proliferation and migration activity during subculturing, and specific CNGs in FCAs B4 and F2 harbouring known EMT-associated genes as VIM, ZEB1, KRAS, HMGA2, ESRP1, MTDH, YWHAZ, and MYC.22,23,36-54. The TiHo-0906 cell line represents a unique cellular model, probably derived from a poorly differentiated cellular subpopulation encompassed in the original tumour.

The cell line was derived from a tumour composed of malignant tubular-epithelial cells, malignant spindle cells, and small anaplastic areas with polygonal cells. Immunohistochemically, tubuli-forming areas showed a higher affinity for CKs while spindle areas were characterized by a mesenchymal profile. Interestingly, polygonal cells in anaplastic areas and TiHo-0906 cells co-expressed CKs and mesenchymal markers. In human breast cancer, this is associated with poor prognosis,27,55,56, in canine and human cellular models, with malignancy.38,55. TiHo-0906 cells displayed an increasing genetic instability during sub-cultivation. Genomic aberrations observed in the cell line were not present in the tumour. This may be related to the fact that DNA isolated from the tumour represents a genomic mixture of all cellular subpopulations included in the sample, whereas the

---

**Figure 6.** HMGA2 and CD44 qPCR-based expression. Comparative expression of (a) HMGA2 and (b) CD44 in TiHo-0906 cells at low (P8) and high (P80) passage versus selected reference tissues (feline testis, and healthy mammary feline tissue, respectively). Data are displayed as mean (SD); *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

---

**Figure 7.** Cell proliferation, growth curves and scratch assay. (a) BrdU cell proliferation assay of TiHo-0906 at low and high passages, absorbance values expressed as Max V (delta 370–492). (b) Growth curves of TiHo-0906 at low and high passages, data are shown as mean (SD). (c–j) Scratch assay, TiHo-0906 P76 cell culture at inverted microscopy (10×).

---
cultivated cells show clonal selection favouring a genomic shift. TiHo-0906 cells protein expression profile was more similar to that of the anaplastic polygonal cells in the tumour. This sub-population was, in fact, the least frequent of the three main cellular components of the tumour. However, considering that during the process of cell line establishment, cells with the higher rate of proliferation are likely to have a better survival chance in culture, the polygonal tumour cells may represent the cellular subpopulation with the faster growth rate and the higher amount of somatic aberrations. These findings also highlight the importance of cellular models as unique tools to study distinct aspects of the oncologic process specifically.

The tumour described in this study may represent a different histological subtype “FMCs with anaplastic and malignant spindle cells” from those included in the last WHO classification. Matsuda et al. reported a
“tubulopapillary carcinoma” with spindle cells (CKs+, and SMA+) in a cat. In contrast, the spindle-cell component in the tumour in this study was negative for CKs but positive for SMA. Paniago et al.24 reported a “feline mammary carcinosarcoma” mainly composed of malignant pleomorphic cells, but no spindle cells were described.25 Similar to the survival of the patient described in this study (three months), the animals reported by Matsuda et al.57 and Paniago et al.24 developed pulmonary metastasis and died three and two months after diagnosis, respectively.57,58

Similar to the tumour described in this study, spindle-hMBCs are characterized by a dominant fibromatosis-like pattern with epithelial cells and limited regions of polygonal cells arranged in clumps or cords.59,60 Immunohistochemically, spindle-hMBCs coexpress CKs (cytokeratin 8/18 [CK8/18], pan-CK, cytokeratin 14 [CK14], and CK5/6) and mesenchymal markers (SMA and Vim).59,60 Spindle cells in these tumours are malignant and display a variable reaction to CKs.61–63 Therefore, a wide spectrum keratin panel (including pan-CK) may be useful for differentiating spindle-hMBCs from other spindle-cell lesions.60 In the tumour described in this study, the spindle cells expressed SMA, CALP and Vim but lacked CKs including pan-CK, which according to the aforementioned would suggest a more likely mesenchymal phenotype. Since the tumour and derived cell line were enriched with EMT traits, and both, polygonal and spindle cells in the tumour expressed CD44, it appears reasonable to consider that both components may have arisen from EMT. However, we cannot completely rule out the presence of some non-neoplastic reactive mesenchymal cells (i.e. myofibroblasts) within the spindle component of the tumour. Considering the presence of both epithelial and mesenchymal components, carcinosarcoma would represent another possible differential diagnosis.64 In dogs, mammary carcinomas (commonly carcinoma and osteosarcoma) are described to express CK8/18 and Vim, but not CALP, p63 and CK14.65. Although this expression profile has not been demonstrated in cats so far, a mammary gland carcinosarcoma is very unlikely in the present case on the basis of histological and immunohistochemical findings. Nonetheless, whether the spindle cells were originated from EMT or represented an additional neoplastic mesenchymal population remains at this point unanswered. In summary, the tumour described in this study shows some similarities with the spindle-hMBC, and it also resembles the FMC cases described by Matsuda et al. and Paniago et al.57,58.

HMGA2 induces EMT.52–26,65,66 In this study, we compared the absolute HMGA2 qPCR-based expression of TiHo-0906 cells with a well-known reference tissue (testis) characterized by high expression of HMGA2.27. The quantitative expression of HMGA2 was significantly higher in TiHo-0906 cells when compared to the reference tissue. These findings are concordant with the CNGs observed in chromosome B4 harbouring HMGA2, which in combination with the characteristic fibroblastoid-shape and the highly migratory ability (demonstrated by in vitro scratching assay) also reveal a profoundly altered mesenchymal gene expression program; consistent with the combined epithelial/mesenchymal phenotype observed.

hMBCs coexpress EMT- and CSCs-features.12 Accordingly, these tumours may originate directly from epithelial cells that have undergone EMT and have therefore acquired CSCs properties, or from pre-existing CSCs expressing EMT-associated markers.12 In FMC and human breast cancer cell lines, CSCs express high levels of CD133, CD44 and low (or none) CD24.30,68,69. In this study, the immunohistochemical expression of CD24 and CD133 was not assessed due to the unavailability of the specific antibodies. However, the fact that only some TiHo-0906 cells expressed p63 when the original tumour was negative, may suggest the presence of some cells with stem cells features which may have acquired a myoepithelial phenotype during sub-cultivation as previously described in a human mammary gland derived cell line.70 All cell types in the tumour expressed CD44, and there was a specific intense membrane staining for CD44 on almost all TiHo-0906 cells. These findings together with the comparative expression profile and HMGA2 expression also suggest that the cell line was originated from the anaplastic polygonal cells in the tumour.

Several well-described breast cancer- and EMT-associated genes were affected by CNVs in the genome of the cell line. As reported by Zhao et al.36 in a study exploring the relationship between EMT-implicated gene expression and CNVs in multiple cancer types in humans,36 we observed that EMT-associated genes were more frequently affected by CNGs than by CNLs. As was mentioned before, most of the EMT-related genes affected by CNVs were located in amplified regions of FCAs B4 and F2. Affected regions of chromosome F2 harboured four of the most commonly EMT-associated genes reported by Zhao et al.36; this includes ESRP1, MTDH, YWHAZ, and MYC.36 Among those, ESRP1 regulates CD44 alternative splicing producing a more malignant isoform (CD44v), promoting invasiveness and distant metastasis in human breast CSCs.31. TiHo-0906 cells overexpress CD44 and displayed CNGs in chromosome F2 harbouring ESRP1 gene. Therefore, TiHo-0906 cell line might be a suitable model for the study of ESRP1 and CD44 as possible therapeutic targets for FMC.

CNVs in chromosome F2 observed in the TiHo-0906 cell lines resemble one of the most common DNA aberrations reported in human breast cancer cell lines—CNVs at the long arm of human chromosome 8 (HSA 8q)—5,25. When comparing the human and feline karyotypes using fluorescence in situ hybridization (FISH), the entire HSA 8q is hybridized by the paint from FCA F4.26,27. CNVs in chromosome F2 observed in the cell line also included some proposed breast cancer-related genes like EIF3E, PKHD1LI, CSMD3, ZHX2, SAMD12, EXT1, MRPL13, MTPB, SNTB1, RNF139, and TATDN1.35. These findings highlight the importance of FCA F2 in FMC development and the close evolutionary relationship with the homologous disease in humans. Additionally, TiHo-0906 cells at low and high passage also displayed CNGs in regions harbouring other known breast cancer-related genes like FOXO3 and MYB (FCA B4), AKT1 (FCA B1), and GATA-3, CCND2, CDK4 and PFDN5 (FCA B4).

CNLs were less common than CNVs. Most CNLs observed affected low or high passages of the cell line, but few of them affected both. For instance, CNLs in chromosome D2, and E3 harbouring PTEN, and RAC1, respectively, were preserved during prolonged subculturing. In contrast, CNLs in chromosome B1 were only observed in low-passaged cells. This chromosomal region harbours the CSMD1, AGPAT5, TUSC3, DLC1, CLDN23, and MFHAS1 cancer-related genes. This aberration corresponds with the most common CNL in human breast cancer cell lines, located at the short arm of human chromosome 8 (HSA 8p).36 Using FISH, feline chromosome B1 labels the entire HSA 8p.3,74. Additional CNLs affecting known breast cancer-, hMBCs-, and EMT-related genes
were only detected after prolonged subculturing; including, FCA A1 containing TERT, BRCA2, RB1, and FOXO1 genes; chromosome A2 harbouring EGFR, TWIST, ML2, and AHR; chromosomes B2, B3, and B4 harbouring CCND3, FOXA1, and MDM2, respectively; and chromosome E1 harbouring NFI, PPM1D, and KSR1.

TiHo-0906 proliferation and migration activity remained comparable during subculturing. Growth curves and doubling times (28.9 h at low passage and 27.4 h at high passage) revealed a high proliferation similar to those reported for previously characterized FMC cell lines. Migration activity was assessed by in vitro scratch assay revealing a shorter time to complete wound closure (approximately 14 h for both, early and high passages) than that previously reported in a recently characterised FMC cell line (approximately 24 h).

After doxorubicin treatment, we observed a significant dose-dependent reduction of viable cells with active metabolism only after 72 h incubation with 100 nM of doxorubicin at low and high passages. These data may suggest a higher doxorubicin resistance of TiHo-0906 cells to that reported in an FMC cell line. Nonetheless, methodological differences in viability assessment and exposure time to doxorubicin make comparison difficult. Resistance to doxorubicin, in terms of metabolic activity remained comparable during subculturing. However, flow cytometric assessment of doxorubicin effects on TiHo-0906 cells revealed a significant increase of apoptotic cells in high-passaged cells when compared to low-passaged cells at all doxorubicin concentrations up to 50 nM (except for 1000 nM). These findings are consistent with the observed two-fold reduction of the IC50 during sub-cultivation, suggesting a reduction in chemoresistance during prolonged subculturing. Similar findings have been reported for different cellular models in humans. However, the specific mechanisms underlying this process are still not clear. To the best of our knowledge, resistance to doxorubicin has not been previously assessed by flow cytometry in FMC-derived cell lines. In this case, we observed a dose-dependent reduction of vital cells with simultaneous increasing of apoptotic cells.

Some immunohistochemical studies in veterinary medicine support the EMT hypothesis to explain the origin of the spindle-cell component on canine mammary metaplastic tumours. There is also evidence suggesting a direct CSCs origin in cell lines derived from canine mammary spindle-cell tumours and sarcomas. Although these two theories have been considered separately, a growing body of literature in human medicine suggests a link between them. In vitro culture models are pivotal to understanding the role of EMT in the oncogenic process of FMC, determining the presence of possible subtypes and developing of new therapeutic approaches. However, the number of established FMC cell lines is still small.

In summary, the present study demonstrated that TiHo-0906 cells co-expressed epithelial and mesenchymal features, and some EMT markers like HMG2A and CD44. Additionally, TiHo-0906 cells are characterized by stable metabolic activity, proliferation rate, and ability to migrate during prolonged subculturing. Furthermore, our results indicate that specific CNVs observed in the cell line harbour a considerable amount of genes implicated in breast cancer development and EMT. CNVs in chromosomes B4 and F2 may be essential for EMT activation in the cat genome and closely resemble some of the typical genomic aberrations observed in human breast cancer. Nonetheless, further studies are necessary to determine the importance of these genomic aberrations in FMCs. The TiHo-0906 cell line represents a unique model consistently displaying EMT-associated traits at baseline. Considering the poor prognosis of affected animals, further studies using in vitro models that closely resemble the uniqueness of the original tumours are of major value for the development of potential therapeutic approaches.

Methods
Primary tumour tissue. The TiHo-0906 cell line was obtained from the primary lesion of a 13-year-old female intact British Shorthair cat diagnosed with spontaneous FMC at clinical stage three according to McNeill et al. The cat was admitted to the Small Animal Clinic at the University of Veterinary Medicine Hannover and underwent unilateral chain mastectomy. No chemotherapy was performed and the cat was euthanised three months after surgery due to pulmonary metastasis. Tissue samples were obtained during the medically necessary surgery, after signed informed owner consent. Consequently, an ethical approval was not required (German Animal Welfare Act, § 7).

Cell culture establishment and maintenance. Immediately after surgery, a tumour tissue sample was placed in a tube with Hank’s Balanced Salt Solution (Gibco) and kept overnight at 4 °C. The remainder of the surgical specimen was fixed in 10% neutral-buffered formalin and prepared for histopathological examination. The selected tumour tissue was minced into small pieces and digested with 4 mL 0.26% collagenase (SERVA) for 3 h at 37 °C with constant stirring. The digested cells were transferred into a sterile 25 cm² cell culture flask containing 5 mL medium 199 (Gibco) supplemented with 20% foetal bovine serum (FBS, Biochrom) and 2% penicillin/streptomycin (Biochrom). The culture was incubated at 37 °C in a humidified atmosphere of 5% CO₂ and split at confluency once or twice a week utilizing 1 mL TrypLE™ (Gibco) as dissociation reagent. Cryogenic preservation was performed once a week at 90% confluence. Cells were dispersed in TrypLE™ and resuspended in growth medium (medium 199 supplemented with 10% FBS, and 2% penicillin-streptomycin). The cell suspension was centrifuged at 1000 g for 10 min, the supernatant was discarded and the cell pellet was resuspended in 1 mL freezing medium (medium 199 supplemented with 20% FBS, 2% penicillin-streptomycin and 10% DMSO [AppliChem]) and transferred into cryogenic storage vials. Cryogenic vials were accommodated in a freezing container (Mr. Frosty, Nalgene), and transferred to a –80 °C freezer, after 24 h the vials were stored in a –150 °C freezer or in a liquid nitrogen storage vessel. TiHo-0906 was considered established when overcoming the passage 30th (P30).

All experiments described below were carried out in triplicate; those involving cells were performed using TiHo-0906 cells, or cell-pellets (5 × 10⁶ cells) at low and high passage (P7–P10, and P76–P80, respectively). For pellet preparation, cells were detached with 1 mL TrypLE™, rinsed with PBS, counted with a PC-based Cellometer (Auto T4, Nexcelom Bioscience), and centrifuged at 1000 g for 10 min. For DNA and RNA
**Histopathology and cytology.** After formalin fixation, paraffin sections (4 μm) of the original tumour were stained with H&E for histopathologic evaluation. The samples were examined under light microscopy and the morphological diagnosis was performed following the WHO classification. Histological grading of the tumour was performed according to the method described by Elston and Ellis 1991 and Castagnaro et al. The cytomorphologic features of the cell line during long-term cultivation were examined microscopically based on H&E stained formalin-fixed, paraffin-embedded cell pellets at low (P7) and high (P80) passages.

**Immunohistochemistry.** Immunophenotyping by the avidin-biotin method was performed in the original tumour and cell pellets of TiHo-0906 (low [P7], and high [P80] passages) as described elsewhere using the following markers (details see Table 6): E-cad, CK8/18, pan-C, CK14, CK5/6, p63, SMA, CALP, Vim, HMG2, CD44, ER, PR, HER-2, COX-2, p53, CLDN-2 and proliferation marker Ki-67. Positive and negative controls used for immunohistochemistry are listed in the Supplementary Table 1. For negative controls, the specific primary antibody was replaced by either an isotype control antibody or normal serum. For positive controls, only tissue samples were used that were sent to the department of pathology for diagnostic purposes not related to the present study. No animal was killed for the generation of positive controls.

**Copy number variation analysis.** Four 10-μm-thick sections were sliced from the tumour FFPE-block, using a microtome (pfm Slide 2003). Afterwads, the sections were deparaffinized and the DNA was isolated with the AllPrep DNA/RNA FFPE kit (QIAGEN) according to manufacturer’s instructions. Before DNA isolation, 4 × 10^6 TiHo-0906 cells (P7 and P76) were homogenized using QIAshredder columns (QIAGEN). DNA isolation was performed with the AllPrep DNA/RNA Mini Kit (QIAGEN) following the manufacturer’s protocol. DNA yields and purity (260/280 ratio) were quantified with the Synergy 2 plate-reader (BioTek).

Starting from the DNA a sequencing library for each sample was prepared using the NEBNext Ultra II DNA Library Preparation Kit for Illumina® (New England Biolabs). Before library preparation, the DNA was sheared by ultrasound to an approximate size of 500 bp. An input of 500 ng DNA was used for each library. Sequencing was conducted on an Illumina NextSeq500 according to manufacturer’s instructions. The program CNV-seq was used for copy-number analyses; using feline healthy mammary tissue as normal reference control and a fixed window size of 1,000,000 bp. Control-tissue was collected from a recently euthanized intact female cat with no pathologies of the mammary gland. The raw results (log2ratios) were smoothed using a circular binary segmentation algorithm implemented in the program “Copynumber” (http://bioconductor.org/packages/release/bioc/html/copynumber.html). Based on the results of the normal reference control, regions with log2-copy-number ratios of >0.25 or <−0.25 were scored as significantly aberrant. Additionally, some bins at telomeres were removed. All bins with smoothed log2-copy-number ratios of >0.25 were scored as amplified (CNGs) and all bins with <−0.25 were scored as deleted (CNLs).

Structural rearrangements (CNGs, and CNLs) observed were compared with those reported in human breast cancers, and were complemented by important EMT-related CNVs reported in multiple human cancer types, specific hMBCs-related CNVs, breast cancer cell lines-related CNVs, and additional cancer-associated genes reported on FMCs.

| Antibody | Type | Clone | Company | References |
|----------|------|-------|---------|------------|
| E-cad    | mouse anti-human* | 36E-cad | BD Biosciences | 9,17 |
| CK8/18   | mouse anti-human* | 5D3 | Novocstra | 9,17 |
| pan-C    | mouse anti-human* | AE1/AE3 | Dako | 9,17 |
| CK14     | rabbit anti-human** | — | Thermo Fischer Scientific | 9,17 |
| CK5/6    | mouse anti-human* | D5/16B4 | Dako | 9,17 |
| p63      | mouse anti-human* | 4A4 | Biolo | 9,17 |
| SMA      | mouse anti-human* | 1A4 | Dako | 9,17 |
| CALP     | mouse anti-human* | CALP | Dako | 9,17 |
| Vim      | mouse anti-human* | V9 | Dako | 9,17 |
| HMG2     | rabbit anti-human** | HMG2 | Lifespan Biosciences | 98 |
| CD44     | Rat anti-mouse CD44* | IM7 | Bio-Rad Laboratories | 93 |
| ER       | mouse anti-human* | 6F11 | AbD Serotec | 93,94,95 |
| PR       | mouse anti-human* | 10A9 | Immunotech | 93,94,95 |
| HER-2    | mouse anti-human* | CB11 | Novocstra | 99,100 |
| COX-2    | goat polyclonal IgG | — | Santa Cruz | 95 |
| p53      | mouse anti-human* | DO-1 | AbD Serotec | 100 |
| CLDN-2   | mouse anti-human* | 12H12 | Thermo Fischer Scientific | 95 |
| Ki-67    | mouse anti-human* | MIB-1 | Dako | 101 |

Table 6. Antibodies and evaluation methods used in this study. *Monoclonal Antibody, **Polyclonal Antibody.
Real-time PCR expression analyses of HMGA2 and CD44. HMGA2 expression is nearly undetectable in adult tissues except for meiotic and post-meiotic cells, in which its expression is high<sup>85</sup>. Consequently, we used feline testis as reference tissue. CD44 is overexpressed in metastatic mammary cancer tissues and CSCs, while its expression in the normal mammary gland is very low<sup>90,96</sup>. Accordingly, we used healthy mammary tissue as reference tissue. Testicular tissue was collected from a healthy tomcat during elective orchectomy and mammary tissue from a recently euthanized (for medical reasons) intact female cat with no pathologies of the mammary gland.

Total RNA was isolated from TiHo-0906 cells (P8 and P80), fresh-frozen feline testicular tissue (HMGA2 reference) and non-neoplastic feline mammary tissue (CD44 reference) according to manufacturer's protocol. The RNA yield and purity (260/280 ratio) were determined using a plate reader (Synergy 2, BioTek). The RNA was stored at −80 °C until use.

HMGA2 and CD44 mRNA levels were measured using absolute quantification, relative to ampiclon-specific standard curves. HMGA2 standard curve sequence and amplification primers were based on a custom canine assay<sup>98</sup> and adjusted to the feline sequence. The feline HMGA2 sequence was obtained by aligning the human exon 2, 3 and 4 sequences (NM_001300918.1) against cat chromosome B4. The feline standard sequence was (5′–3′): HMGA2 cat standard: AGAGTCCTCCAAAAAGCAGCTCAAAGAAAGACAGCACTGGAGAAAAACGGGCAAGGCGACCGAGAAATGGGCAA. The primers were (5′–3′): HMGA2 cat fw: AGTCCTCCAAAAAGCAGCTCAAAG and HMGA2 cat rv: GCCATTTCCTGGTCTGGCTCT. CD44 standard curve sequence and amplification primers were based on Ensembl-ID ENSFCAT000000085894.4, lying on the exon 3 and 4 border. CD44 cat standard (5′–3′): TACATCGGTCACAACCTGGCATTGTTGAGGACCACTATATACACCTTGAACCCTGGCCTATA. The primers were (5′–3′): CD44 cat fw: CACCTCCACACACGTTTCAGCAG and CD44 cat rv: CAGTACGGGTTTGGAGTGTTCC.

Real-time PCR was carried out using the Mastercycler ep realplex Real-Time PCR System (Eppendorf). The qPCR reactions were performed using the QuantiTect SYBR® Green RT-PCR Kit (QIAGEN) in a total reaction volume of 20 μL and a primer concentration of 1 μL of 10 μM stock, for each primer. 100 ng of isolated total RNA were used per sample to measure mRNA copy numbers. The standard curves resulted from seven dilution steps, ranging from 10<sup>2</sup> to 10<sup>6</sup> copies. PCR conditions were as follows: 50°C for 30 min cDNA synthesis, 95°C for 15 min initial denaturation, 40 cycles at 94 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s, completed by a melting curve analysis ranging from 102 to 108 copies. PCR conditions were as follows: 50 °C for 30 min cDNA synthesis, 95 °C for 15 min initial denaturation, 40 cycles at 94 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s, completed by a melting curve analysis. All samples including the dilutions of the standard curve were measured in triplicate.

**Growth behaviour and migration activity.** TiHo-0906 cells proliferation was measured via Cell Proliferation ELISA, BrdU (colorimetric) Assay (Roche). TiHo-0906 cells (7.5 × 10<sup>5</sup> cells/well) were seeded at low (P7) and high (P76) passages were seeded in 96-well plates in octuplets and incubated at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. BrdU was added after 24 h, 48 h, 72 h and 86 h and incubated for 18 h each time. BrdU absorbance was reported<sup>39</sup>. Cells at low (P7) and high (P76) passages were cultured in 6 well culture plates in triplicates, once the medium was aspirated and the cells were treated with different dilutions of doxorubicin (1 nM, 10 nM, 100 nM, 500 nM, 1000 nM, and 2000 nM [3 mL/well]) and then re-incubated for 72 h. After this period, media containing non-adherent and dead cells were collected. Adherent cells were dissociated with 1 mL TrypLE<sup>™</sup> and centrifuged (1000 rpm for 6 min) together with the previously collected media. The supernatant was discarded, and cell pellets were resuspended in 500 μL of 1X Binding Buffer. Cell suspensions were incubated (10 min at room temperature in the dark) with 5 μL Annexin V-FITC and 1 μL SYTOX Green Dye (Annexin V-FITC Detection Kit plus, PromoCell). Flow cytometry analysis was performed using the CellQuest<sup>™</sup> software package on a FACSCalibur<sup>™</sup> flow cytometer. In order to analyze the percentage of dead cells, the flow cytometry data was analyzed using the CellQuest® Cell Population Analysis Software.

**Sensitivity to doxorubicin.** The anti-proliferative effects of doxorubicin on TiHo-0906 cells were evaluated by assessing the cells metabolic activity with the CellTiter 96<sup>®</sup> MTS Proliferation Assay (Promega). Cells at low (P7) and high (P76) passages were seeded in 96-well plates (7.5 × 10<sup>5</sup> cells/well) and incubated for 18 h. The medium was aspirated and the cells were treated with different dilutions of doxorubicin (1 nM, 10 nM, 100 nM, 200 nM, 1000 nM, and 2000 nM [200 μL/well]). The inhibitory activity of doxorubicin on TiHo-0906 cells at low and high passage was determined by xTT assay<sup>91</sup> and adjusted to the feline sequence. The feline CD44 sequence was obtained by aligning the human exon 3 and 4 border. CD44 cat standard: AGTCCCTCCAAAAAGCAGCTCAAAGAAAGACAGCACTGGAGAAAAACGGGCAAGGCGACCGAGAAATGGGCAA. The primers were (5′–3′): CD44 cat fw: CACCTCCACACACGTTTCAGCAG and CD44 cat rv: CAGTACGGGTTTGGAGTGTTCC.

Real-time PCR was carried out using the QuantiTect SYBR<sup>®</sup> Green RT-PCR Kit (QIAGEN) in a total reaction volume of 20 μL and a primer concentration of 1 μL of 10 μM stock, for each primer. 100 ng of isolated total RNA were used per sample to measure mRNA copy numbers. The standard curves resulted from seven dilution steps, ranging from 10<sup>2</sup> to 10<sup>6</sup> copies. PCR conditions were as follows: 50°C for 30 min cDNA synthesis, 95°C for 15 min initial denaturation, 40 cycles at 94 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s, completed by a melting curve analysis. All samples including the dilutions of the standard curve were measured in triplicate.

**Apoptosis induced by doxorubicin.** TiHo-0906 cells (P7 and P77) were seeded in 6-well plates (2 × 10<sup>5</sup> cells/well) and incubated for 18 h at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>. Afterwards, the cells were exposed to different dilutions of doxorubicin (1 nM, 10 nM, 50 nM, 100 nM, 200 nM, 500 nM, 1000 nM, and 2000 nM [3 mL/well]) and then re-incubated for 72 h. After this period, media containing non-adherent and dead cells were collected. Adherent cells were dissociated with 1 mL TrypLE<sup>™</sup> and centrifuged (1000 rpm for 6 min) together with the previously collected media. The supernatant was discarded, and cell pellets were resuspended in 500 μL of 1X Binding Buffer. Cell suspensions were incubated (10 min at room temperature in the dark) with 5 μL Annexin V-FITC and 1 μL SYTOX Green Dye (Annexin V-FITC Detection Kit plus, PromoCell). Flow cytometry analysis was performed using the CellQuest<sup>™</sup> software package on a FACSCalibur<sup>™</sup> flow cytometer. In order to analyze the percentage of dead cells, the flow cytometry data was analyzed using the CellQuest® Cell Population Analysis Software.
was performed using a MACSQuant® Analyzer 10 (Miltenyi Biotec). Dead cells treated with 1 mL 0.2% Triton™ X-100 (Sigma-Aldrich) and non-treated viable cells were used to set the gates. Annexin V-FITC and SYTOX Green Dye were measured in the FL-1 channel, and results were analysed with FlowJo Version 7.6.5 (FlowJo, Ashland, OR, USA). For data analysis, cell debris on the left-side of the plot were set as negative gate. Afterwards, intact cells were gated for viability on three different populations: viable, apoptotic, and dead.

Statistical analysis. All statistical analyses were performed using SAS software 7.1 (SAS Institute Inc., Cary, NC, USA); the significance threshold was set at p ≤ 0.05. Data distribution was tested using Shapiro-Wilk test. Statistical analysis of BrdU cell proliferation test, growth curves, and real-time PCR expression analyses of HMG2 and CD44 were performed using a 2-tailed Mann-Whitney-U test. Times to in vitro wound-scratch closure were analysed by two-tailed t-test. Results from MTS cell proliferation test and flow cytometry were evaluated using Wilcoxon's two-sample test.

References
1. Hayes, A. A. & Mooney, S. Feline mammary tumors. Vet. Clin. North Am. Small Anim. Pract. 15, 513–20 (1985).
2. Misdorp, W., Else, R., Helin, E. & Lipscomb, T. Histological classification of mammary tumors of the dog and cat. (1999).
3. Zappulli, V. et al. Prognostic Evaluation of Feline Mammary Carcinoma: A Review of the Literature. Vet. Pathol. 52, 46–60 (2015).
4. Wiese, D., Thawai, T., Yuzbasiyan-gurkan, V. & Küpöl, M. Feline mammary basel-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 13, 403 (2013).
5. Ellis, L. et al. In Pathology and Genetics of Tumours of the Breast and Female Organs. WHO Classification of Tumours. (eds Tavassoli, F. A. & Devilee, P.) 37–38 (IARCPress, 2003).
6. McKinnon, E. & Xiao, P. Metastatic Carcinoma of the Breast. Arch Pathol Lab Med 139, 819–822 (2015).
7. Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116–4124 (2009).
8. May, C. D. et al. Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression. Breast Cancer Res. 13, 202 (2011).
9. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: emerging as an axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010).
10. Boyer, B., Vallés, A. M. & Edme, N. Induction and Regulation of Epithelial–Mesenchymal transitions. 60, 1091–1099 (2000).
11. Radisky, E. S. & Radisky, D. C. Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast Cancer. J. Mammary Gland Biol. Neoplasia 15, 201–212 (2010).
12. Oom, M. L., Ikeu, A. A., Tan, S. Y. & Tan, P. H. Cancer stem cell and epithelial–mesenchymal transition markers predict worse outcome in metastatic carcinoma of the breast. Breast cancer Res. Treat. 150, 31–41 (2015).
13. Morel, A.-P. et al. Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition. PLoS One 3, 1–7 (2008).
14. Mani, S. A. et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 133, 704–715 (2008).
15. Battula, V. L. et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435–1445 (2010).
16. Arumugam, T. et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820–5828 (2009).
17. Carsons, J. et al. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines. Cell Commun. Signal. 13, 26 (2015).
18. Hanahan, D. & Weinberg, R. A. The Hallmarks of Cancer. Cell 100, 57–70 (2000).
19. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–74 (2011).
20. Tsai, J. H. & Yang, J. Epithelial–mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192–2202 (2013).
21. Kaluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–1428 (2009).
22. Watanabe, S. et al. HMG2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am. J. Pathol. 174, 854–868 (2009).
23. Zha, L. et al. HMG2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig. Dis. Sci. 58, 724–733 (2013).
24. Qajiqian, D. O. N. G. et al. HMG2–FOX2L2 axis regulates metastases and epithelial-to-mesenchymal transition of chemoresistant gastric cancer. Clin. Cancer Res. 23, 3461–3473 (2017).
25. Zhao, X.-P. et al. Overexpression of HMG2 promotes tongue cancer metastasis through EMT pathway. J. Transl. Med. 14, 26 (2016).
26. Morishita, A. et al. HMG2 is a driver of tumor metastasis. Cancer Res. 73, 4829–4829 (2013).
27. Vora, H. H. et al. Cytokeratin and vimentin expression in breast cancer. Int. J. Biol. Markers 24, 38–46 (2009).
28. Cho, S. H. et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int. J. Oncol. 41, 211–218 (2012).
29. Riccardo, S. et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 64, 937–946 (2011).
30. Barbieri, E. et al. Isolation of stem-like cells from spontaneous feline mammary carcinomas: Phenotypic characterization and tumorigenic potential. Exp. Cell Res. 318, 847–860 (2012).
31. Shlien, A. & Malkin, D. Copy number variations and cancer. Genome Med. 1, 1–9 (2009).
32. Ross, J. et al. Genomic Profiling of Advanced-Stage, Metastatic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options. Arch. Pathol. Lab. Med. 139, 642–649 (2015).
33. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353–360 (2012).
34. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
35. Saito, S., Morita, K. & Hirano, T. High frequency of common DNA copy number abnormalities detected by bacterial artificial chromosome array comparative genomic hybridization in 24 breast cancer cell lines. Hum. Cell 22, 1–10 (2009).
36. Zhao, M., Liu, Y. & Qu, H. Expression of epithelial-mesenchymal transition-related genes increases with copy number in multiple cancer types. Oncotarget 7, 24688–99 (2016).
37. Lacroix, M. & Leclercq, G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83, 249–289 (2004).
38. Caceres, S. et al. Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One 10, e0122277 (2015).
39. Borges, A., Adega, F. & Chaves, R. Establishment and characterization of a new feline mammary cancer cell line, FkMTp. Cytotechnology 68, 1529–43 (2016).
40. Sayasith, K., Sirios, J. & Doré, M. Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Vet. Pathol. 46, 423–429 (2009).
41. Millanta, F., Citi, S., Dellà Santa, D., Porciani, M. & Poli, A. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. *Breast Cancer Res. Treat.* 98, 115–20 (2006).
42. Flores, A. R., Réma, A., Carvalho, F., Faustino, A. & Dias Pereira, P. Reduced expression of claudin-2 is associated with high histological grade and metastasis of feline mammary carcinomas. *J. Comp. Pathol.* 150, 169–74 (2014).
43. Hughes, K. & Dobson, J. M. Prognostic histopathological and molecular markers in feline mammary neoplasia. *Vet. J.* 194, 19–26 (2012).
44. Castagnaro, M. et al. Ki-67 index as indicator of the post-surgical prognosis in feline mammary carcinomas. *Res. Vet. Sci.* 65, 223–6 (1998).
45. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Res. Treat.* 12, R68 (2010).
46. Hammer, S. C. et al. Longitudinal claudin gene expression analyses in canine mammary tissues and thereof derived primary cultures and cell lines. *Int. J. Mol. Sci.* 17, 1655 (2016).
47. Li, C. P. et al. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma. *Carcinogenesis* 37, 557–566 (2016).
48. Beha, G. et al. Morphology of the Myoepithelial Cell: Immunohistochemical Characterization from Resting to Motile Phase. *Sci. World J.* 2012, 1–8 (2012).
49. Gartner, F., Geraldes, M., Cassali, G., Rema, A. & Schmitt, F. DNA Measurement and Immunohistochemical Characterization of Epithelial and Mesenchymal Cells in Canine Mixed Mammary Tumours: Putative Evidence for a Common Histiogenesis. *Vet. J.* 158, 39–47 (1999).
50. Sarrió, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Res.* 68, 989–997 (2008).
51. Aigner, K. et al. The transcription factor ZEB1 (SEFI1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. *Oncogene* 26, 6979–6988 (2007).
52. Taube, J. H. et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metastatic breast cancer subtypes. *Proc. Natl. Acad. Sci. USA* 107, 15449–54 (2010).
53. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting micro-RNAs. *Nat. Cell Biol.* 11, 1487–95 (2009).
54. Lin, M. et al. Copy number gain and oncogenic activity of YWHAZ/14:3-3C, in head and neck squamous cell carcinoma. *Int. J. Cancer* 125, 603–611 (2009).
55. Healey, M., Whiteside, C., Maxwell, P. & Toner, P. Vimentin expression in benign and malignant breast epithelium. *J. Clin. Pathol.* 46, 441–445 (1993).
56. Korsching, E. et al. The origin of vimentin expression in invasive breast cancer: Epithelial- mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? *J. Pathol.* 206, 451–457 (2005).
57. Matsuda, K. et al. Tubulopapillary Carcinoma with Spindle Cell Metaplasia of the Mammary Gland in a Cat. *J. Vet. Med. Sci.* 70, 479–481 (2008).
58. Paniago, J. D. G. et al. Epithelial-mesenchymal transition in human hepatocellular carcinoma. *Cell Genet.* 741–5 (1998).
59. Goldschmidt, M. H., Peña, L. & Zappulli, V. In *Tumours in Domestic Animals* (ed. Meuten, D. J.) 748 (John Wiley & Sons, Inc, 2016).
60. Luo, Y., Li, W. & Liao, H. HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells. *Oncol. Lett.* 5, 1353–1356 (2013).
61. Sun, M. et al. HMGA2/ET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. *Proc. Natl. Acad. Sci. USA* 110, 9920–9925 (2013).
62. Chieffi, P. et al. HMGA1 and HMGA2 protein expression in mouse spermatogenesis. *Carcinogenesis* 21, 3644–3650 (2002).
63. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, Adalberto Morrison, S. J. & Clarke, M. E. Prospective identification of tumorigenic breast cancer cells. *Proc. Natl. Acad. Sci. USA* 100, 3983–98 (2003).
64. Pagán, J. et al. Feline mammary carcinoma stem cells are tumorigenic, radioreistant, chemo-resistant and defective in activation of the ATM/p53 DNA damage pathway. *Vet. J.* 196, 414–423 (2013).
65. Chua, H. L. et al. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: Potential involvement of ZEB-1 and ZEB-2. *Oncogene* 26, 711–724 (2007).
66. Hu, J., Li, G., Zhang, P., Zhuang, X. & Hu, G. A CD44v+ subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. *Cell Death Dis.* 8, e2679 (2017).
67. Jonsson, G. et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. *Genes. Chromosomes Cancer* 46, 543–558 (2007).
68. Wiensberg, J. et al. Conservation of human vs. feline genome organization revealed by reciprocal chromosome painting. *Cytogenet. Cell Genet.* 77, 211–7 (1997).
69. Yang, P. et al. Reciprocal chromosome painting illuminates the history of genome evolution of the domestic cat, dog and human. *Chromosom. Res.* 8, 393–404 (2000).
70. Minke, J. M. et al. Identification of two distinct epithelial cell lines from a single feline mammary carcinoma with different tumorigenic potential in nude mice and expressing different levels of epidermal growth factor receptors. *Cancer Res.* 51, 4028–37 (1991).
71. Unlü, I. S. et al. Establishment and characterization of a new cell line derived from feline mammary tumor. *J. Vet. Med. Sci.* 60, 931–5 (1998).
72. Uyama, R. et al. Establishment and characterization of eight feline mammary adenocarcinoma cell lines. *J. Vet. Med. Sci.* 67, 1273–6 (2005).
73. Penzo, C., Ross, M., Muirhead, R., Else, R. & Argyle, D. J. Effect of recombinant feline interferon-α alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours. *Vet. Comp. Oncol.* 7, 222–229 (2009).
74. Kruyczynski, A. & Kiss, R. Evidence of a direct relationship between the increase in the *in vitro* passage number of human non-small-cell lung cancer primocultures and their chemo-sensitivity. *Anticancer Res.* 13, 507–13 (1993).
75. Hellmen, E., Møller, M., Blankenstein, M. A., Anderson, J. & Westermarck, J. Expression of different phenotypes in cell lines from canine mammary spindle-cell tumours and osteosarcomas indicating a pluripotent mammary stem cell origin. *Breast Cancer Res. Treat.* 61, 197–210 (2000).
Acknowledgements
The authors wish to thank Kerstin Rohn, Regina Carlson, Heike Thiemeyer, Eva Packeiser, Annika Mohr, Camila Penter, Florenza Lüder Ripoli, Tatjana Harting, Susanne C. Hammer, Alexandra Anders, and Claudia Windhövel, and for their excellent technical assistance, valuable comments, and suggestions.

Author Contributions
José Luis Granados-Soler, Ingo Nolte, Hugo Murua Escobar, and Marion Hewicker-Trautwein performed the primary study design; Ingo Nolte, Hugo Murua Escobar, Daniela Betz, and Marion Hewicker-Trautwein performed the manuscript revision, and final approval; Johannes Junginger and Marion Hewicker-Trautwein performed the histopathology and immunohistochemistry; Kirsten Bornemann-Kolatzki, Julia Beck and Bertram Brenig performed the DNA sequencing and CNVs; Jan Torben Schille performed the qPCR experiments, José Luis Granados-Soler performed the cell cultivation, growth curves, scratching assay, proliferation assay, flow cytometry, DNA, and RNA isolation, qPCR and CNVs data analysis, analysed the data and wrote the paper.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-31682-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018